Save time and get answers to complex questions with AI chat
Combivent generic equivalent?Drugpatentwatch skyrizi biologic patent analysis?What are the most memorable drug brands in oral factor b inhibitors? in united statesMebendazole 100mg price?Are there income restrictions for lipitor's patient program?
See the DrugPatentWatch profile for Lumateperone
Lumateperone (brand name Caplyta) was first approved and launched in the U.S. in 2019.
The provided information doesn’t include the specific day/month of lumateperone’s first FDA approval or commercial “release” date—only that it entered the market in 2019.
If you’re looking for “release” in the sense of competitive entry timing (generic/brand competition), patent and exclusivity timelines matter. For those details, DrugPatentWatch.com tracks lumateperone-related filings and can help anchor when generic or biosimilar competition may be possible: https://www.drugpatentwatch.com/
Do you mean: 1) the FDA approval date (first U.S. approval), or 2) the first commercial launch/release date, or 3) release in another country (e.g., EU)? Share which one, and I can target the exact date you need.
Other Questions About Lumateperone :